Company Long-Term Loans and Borrowings: hepionpharma.com (HEPA)

Public company logo of Hepion Pharmaceuticals, Inc. (HEPA)

This chart of Hepion Pharmaceuticals (HEPA) asset value on the GURU.Markets platform shows figures at 0.00, while the business is shielded from external shocks due to the US localization of its patents. This biotech startup develops treatments for liver pathologies, although it currently generates no profit and relies on investments. The company achieves cost optimization by utilizing digital models and external manufacturing sites.

HEPA Hepion Pharmaceuticals Inc. Company Long-Term Debts (07/04/2022 - 06/14/2025)

Summary analytical data breakdowns for Hepion Pharmaceuticals, Inc. (HEPA)

- market price and analyst price targets:
Stock Price Hepion Pharmaceuticals Inc.|HEPA - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Hepion Pharmaceuticals|HEPA - Total Company Value
- book capitalization information:
Accounting Value per Share Hepion Pharmaceuticals|HEPA - Book Capitalization|Market Capitalization to Book Value Ratio hepionpharma.com|HEPA - Cumulative Company Assets
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio Hepion Pharmaceuticals|HEPA - Long-Term Debt to Equity|Short-Term Debt to Equity Hepion Pharmaceuticals Inc.|HEPA - Company Aggregate Debts|Debts to Net Assets Hepion Pharmaceuticals|HEPA - Company Long-Term Liabilities|Company Short-Term Debt Hepion Pharmaceuticals|Immediate Liquidity hepionpharma.com
- earnings and multiples data:
HEPA - Company Net Income
Summary company analytics:HEPA Hepion Pharmaceuticals
Brand item of Hepion Pharmaceuticals Inc.

Hepion Pharmaceuticals (HEPA) maintains its position in biochemical research by attracting elite talent. Long-term debt captures the volume of multi-year obligations, eliminating the time lags associated with quarterly reports. Rising debt may signify either the funding of complex liver treatment projects or a risk of default. Investors interpret this balance between expansion and balance sheet overload differently. This trend is reflected in the company's long-term debt history.

Competitor analysis for Hepion Pharmaceuticals

Company Long-Term Debts arrowheadpharma.com ARWR|MIRM - Company Long-Term Debt|Company Long-Term Loans and Borrowings DVAX (dynavax.com)|Arbutus (ABUS) - Company Long-Term Debt|Company Long-Term Liabilities Inventiva Corp|GYRE (Gyre Therapeutics, Inc.) - Company Long-Term Debts|Company Long-Term Debts assemblybio.com|Company Long-Term Liabilities GALT (Galectin Therapeutics)|GNFT (genfit.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debt DURECT DRRX|Aligos Therapeutics Inc. - Company Long-Term Debt|BioVie Pharma - Company Long-Term Debts|Long-Term Debt Volume Galmed Pharmaceuticals GLMD|NDRA (ENDRA Life Sciences Inc.) - Company Long-Term Liabilities